Screener
McKesson MCK North American Pharmaceutical — Restructuring Charges
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: McKesson’s 10-K, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal year
- FY2026
- Accession
- 0000927653-26-000069
| (In millions) | Year Ended March 31, 2026 / North American Pharmaceutical (1) | Year Ended March 31, 2026 / Prescription Technology Solutions (2) | Year Ended March 31, 2026 / Medical-Surgical Solutions (3) | Year Ended March 31, 2026 / Corporate & Other (4) | Total |
|---|---|---|---|---|---|
| Severance and employee-related costs, net | $9 | $3 | $14 | $(1) | $25 |
| Exit and other-related costs (5) | 3 | — | 37 | 151 | 191 |
| Asset impairments and accelerated depreciation | 12 | 17 | (8) | 8 | 29 |
| Total | $24 | $20 | $43 | $158 | $245 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is McKesson's north american pharmaceutical — restructuring charges?
- McKesson (MCK) reported north american pharmaceutical — restructuring charges of $16M in Q1 2026.
- What does north american pharmaceutical — restructuring charges mean?
- This metric aggregates all costs associated with formal restructuring programs within the North American Pharmaceutical segment, including severance, facility closures, and system migrations. It provides a comprehensive view of the financial investment required to execute strategic organizational changes.
Ask your AI about McKesson's north american pharmaceutical — restructuring charges.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude